|
NAA20 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62492241884138E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.10862446895044E-15 |
| Normal-vs-Stage2 |
7.73600000000263E-05 |
| Normal-vs-Stage3 |
1.68687286361546E-12 |
| Normal-vs-Stage4 |
1.62447832963153E-12 |
| Stage1-vs-Stage2 |
2.302800E-01 |
| Stage1-vs-Stage3 |
1.703390E-01 |
| Stage1-vs-Stage4 |
4.17380000000689E-05 |
| Stage2-vs-Stage3 |
4.854200E-02 |
| Stage2-vs-Stage4 |
1.278570E-03 |
| Stage3-vs-Stage4 |
4.963900E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
1.91019999817854E-08 |
| Normal-vs-Asian |
1.63424829224823E-12 |
| Caucasian-vs-AfricanAmerican |
6.982800E-01 |
| Caucasian-vs-Asian |
5.039800E-01 |
| AfricanAmerican-vs-Asian |
9.563800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.64153152077051E-14 |
| Normal-vs-Female |
1.63291602461868E-12 |
| Male-vs-Female |
6.544200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.62447832963153E-12 |
| Normal-vs-Age(41-60Yrs) |
1.37678757283766E-12 |
| Normal-vs-Age(61-80Yrs) |
2.68050026619449E-10 |
| Normal-vs-Age(81-100Yrs) |
4.800600E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
7.691000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
6.058600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.996400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.713800E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.080200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.986000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.351800E-02 |
| Classical-VS-Follicular |
1.50018999999224E-05 |
| Classical-VS-Other |
4.554000E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
3.79209999956664E-07 |
| Tall-VS-Other |
5.804100E-02 |
| Tall-VS-Normal |
2.23643326080492E-12 |
| Follicular-VS-Other |
3.714000E-01 |
| Follicular-VS-Normal |
6.972200E-04 |
| Other-VS-Normal |
4.084100E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
2.42972308939216E-12 |
| Normal-vs-N1 |
6.66133814775094E-16 |
| N0-vs-N1 |
5.100400E-03 |
|
|
